Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Ferronordic’s investor presentation 11 November 2022

Ferronordic’s interim report for the third quarter 2022 will be published on 11 November 2022 at 07:30 CET. A presentation of the report will be held the same day at 10:00 CET.Ferronordic’s interim report for the third quarter 2022 will be published on 11 November 2022 at 07.30 CET and will be accessible at www.ferronordic.com. Ferronordic invites investors, analysts and the media to a presentation where Lars Corneliusson, CEO, and Erik Danemar, CFO, comment on the report. The presentation will be held on 11 November 2022 at 10:00 CET and can be followed via telephone conference or

NoHo Partners Plc's Q1-Q3 2022 Interim Report briefing on 8 November 2022 at 10 EET at Restaurant Teatteri

NoHo Partners Plc INVESTOR NEWS 28 OCTOBER 2022 AT 13:00 EET NoHo Partners Plc's Q1-Q3 2022 Interim Report briefing on 8 November 2022 at 10 EET at Restaurant Teatteri NoHo Partners Plc will publish its Interim Report for 1 January – 30 September 2022 on Tuesday 8 November 2022 approximately at 8:15 EET, after which it will be available at www.noho.fi/en. A briefing for the media, analysts and investors will be organized on the same day at 10:00 EET at Restaurant Teatteri’s Kello bar located at Pohjoisesplanadi 2, 00130 Helsinki. At the event, NoHo Partners’ CEO Aku Vikström

Smoltek publishes prospectus in connection with rights issue of units

This press release is an English version of the previously published Swedish version, which has interpretive precedence.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Smoltek Nanotech Holding AB (“Smoltek” or the “

Pediatric diabetes trial with ProTrans gets green light for phase II part

NextCell Pharma AB ("NextCell") announces that the Data Safety Monitoring Board has recommended professor Per-Ola Carlsson to continue with the phase II part of the pediatric study in type-1 diabetes with ProTrans, ProTrans-Young.The first part of ProTrans-Young is a safety part (phase Ib) where all patients are treated at Uppsala University Hospital.  3 patients aged 12-18 years first receive treatment and are then followed by 3 patients aged 7-11 years.  After all 6 patients have been on a 3 month follow-up examination, there is a review of data with regards to safety by the Data Safety

Invitation to presentation of First Camp Group's report for the third quarter of 2022

First Camp Group AB's report for the third quarter of 2022 will be published on Tuesday, November 1, 2022 at around 08:00.A digital conference will be held at 13:00. At the conference, Johan Söör, CEO and Göran Meijer, CFO, will present the report, followed by a question and answer session. The presentation will be held in English. A presentation and video link to the conference will be available at https://corporate.firstcamp.se/en/for-investors from the time the report for the third quarter of 2022 is published.

Enersense International Plc’s January-September 2022 Business Review: Order backlog grew significantly

Enersense International PlcStock Exchange Release October 28, 2022 at 12:00 p.m.This release is a summary of Enersense International Plc’s January-September 2022 Business Review. The company complies with the semiannual reporting in accordance with the Finnish Securities Markets Act and discloses business reviews for the first three and first nine months of the year, which present key information regarding the company’s financial position and development. The financial information presented in the business review is unaudited. The complete report is attached to this release as a pdf file.

Passenger car preheating produces as much particulate emissions as driving dozens of kilometres

A new study from Finland, conducted by the University of Eastern Finland and Tampere University, measured particulate emissions from passenger car preheating with an auxiliary heater in sub-zero conditions. The preheating emissions were compared to calculated emissions from driving to determine the driving distance corresponding to the preheating emissions under current emissions standards.Publishing their findings in Atmospheric Environment: X, the researchers measured auxiliary heater (AH) particulate emissions from the preheating of three gasoline, and three diesel cars for a half an

GSK terminates RA project

Yesterday, the British pharma giant GSK announced that they are terminating the development of the candidate otilimab for rheumatoid arthritis after it failed to reach the primary endpoint in a phase III study in patients with an inadequate response to biological DMARDs and/or JAK inhibitors.Read the full article at biostock.se:https://www.biostock.se/en/2022/10/gsk-terminates-ra-project/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Newsletter October 2022 – Steps forward during Breast Cancer Awareness Month

This October is Breast Cancer Awareness Month, known for the Pink Ribbon, a campaign to raise awareness about the impact of breast cancer and the importance of early detection. For this newsletter, Cline will share exciting news about the advances in the field and how CellRACE is progressing in its journey to save lives of patients with breast cancer.Breast cancer is the most common cancer in Europe and the leading cause of cancer death among women[1.] Each year more than 7,500 people are diagnosed with breast cancer in Sweden, which is around 20 people a day[2]. Due to early detection and

Veidekke: New commission for SINTEF in Trondheim

Veidekke has signed a contract with SINTEF Energi AS to build SINTEF Horizon, an eco-certified commercial building on the Gløshaugen university campus in Trondheim. The commission is a design and build contract valued at NOK 280 million, excluding VAT.The new building will total 11,000 m[2 ]in size, of which 6,500 m[2] is a new build and the remaining 4,500 m[2] is rehabilitation of an existing office building. SINTEF Horizon will accommodate office spaces, areas designed for interaction and research, and a canteen for employees and other users of the campus. The project aims to become a

McLaren Proton Therapy Center – Karmanos Cancer Institute, selects RayStation for proton planning

RaySearch Laboratories AB (publ) announces that McLaren Proton Therapy Center in Flint, Michigan, has placed an order for the treatment planning system RayStation®*.The McLaren Proton Therapy Center has a long history of proton treatments in the Detroit and eastern Michigan area. The center is the only National Cancer Institute (NCI) - designated comprehensive cancer center in metropolitan Detroit and one of just 51 centers of its kind in the United States. Since 2018, the center's capacity has grown, and they have recently treated their 600th patient. The RayStation purchase will

Gold for Wallenstam’s headquarters

Wallenstam’s headquarters has been awarded the gold prize in the Environmental Building In-Use (Miljöbyggnad iDrift) category in the Sweden Green Building Awards 2022 competition. Both Wallenstam’s headquarters and the regional office in Stockholm have been recently certified in the gold category according to the Environmental Building In-Use rating system developed by the Swedish Green Building Council (SGBC).The motivation for the award reads as follows: “The winning property is a good example which demonstrates that a building can be sustainable over time. Although it is an older

Nomination committee for Scandic’s AGM 2023 appointed

In accordance with the instruction to the Nomination Committee, Scandic’s Nomination Committee is made up of Scandic’s three largest shareholders as per August 31, 2022, and the Chair of the Board of Directors. Prior to the Annual General Meeting 2022, the Nomination Committee is composed as follows:· Karl Swartling, Stena Sessan AB, Chair of the Nomination Committee · Dick Bergqvist, AMF · Trygve Hegnar, Periscopus AS · Per G. Braathen, Chair of the Board of Directors · Camilla Köhler, General Counsel and Secretary of the Nomination Committee Shareholders wishing to submit

Smoltek publishes newsletter on technical progress, recruitments and the company's rights issue

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (“Smoltek”) publishes a new edition of its newsletter aimed at shareholders, investors and other stakeholders within the company's business areas Semiconductors (ultra-thin capacitors) and Hydrogen (high-performance cell material for hydrogen gas production).The newsletter highlights presentations made at two international conferences on Smoltek’s technical achievements in ultra-thin capacitors and high-performance cell material to

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 222 - 28 OCTOBER 2022 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 158/22. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor

INTELLilight from TYRI has been awarded the Red Dot Design Award for its innovative design

Intelligent work lighting systems that offer new possibilities for both the user and the installer. INTELLilight is a flexible lighting solution for work machines that can be adapted to the operators needs and to the environment with which they are working in.The app that gave the award It’s the app’s design and functionality that raised the eyebrows of the Red Dot Award jury.  Via the app you can control all the lighting, by either grouping, adjusting the lighting strength or colour temperature; all achieved from outside the operator’s area and entirely based on the driver's preferences

Nomination Committee for Bravida Holding AB’s AGM 2023

In accordance with the decision at Bravida Holding AB’s Annual General Meeting on 5 May 2023, the largest shareholders in terms of votes at the end of July 2022 has appointed the following persons to be part of Bravida’s Nomination Committee ahead of the Annual General Meeting of 2023.· Joachim Spetz, Swedbank Robur fonder (Chairman) · Lovisa Runge, Fjärde AP-fonden · Henrik Didner, Didner & Gerge · Fredrik Arp, Chairman Bravida Holding AB (adjunct member) Shareholders who wish to submit proposals to Bravida's nomination committee are welcome to submit their proposals by e-mail

Interim Report Q3 January-September 2022

Customer demand was very strong, resulting in the second highest quarterly net sales level ever. Our modern connected lighting solutions help customers reduce energy consumption by up to 90%.The third quarter: · Order intake was MSEK 1,891 (1,895), a decrease of -0.2% adjusted to -5.2% for currency effects of MSEK +94 · Net sales were MSEK 2,081 (1,745), an increase of +19.3% adjusted to +13.0% for currency effects of MSEK +109 · Operating profit was MSEK 218.8 (184.2), an increase of +18.8% with an operating margin of 10.5 (10.6)% · Earnings after tax were MSEK 156.9 (127.6)

Inhalation Sciences signs IRS order worth 1.17 million SEK with large generic pharma company

Inhalation Sciences has signed a new contract worth 1.17 million SEK (107,600 Euros) for an Inhalation Research Service (IRS) project aiming to establish differences in the dissolution profiles between a generic inhaled therapy and its reference drug – a key component of bioequivalence.Dissolution data are a crucial component of bioequivalence, a key requirement that  a generic drug needs to comply to for regulatory approval. Bioequivalence is particularly challenging to define for inhaled drugs - a fast-growing market segment that is forecast to grow from 17.5 BUSD (2021) to 38.45 BUSD by

BioStock: Important year for life science as Sweden holds the EU presidency

During the first half of 2023, all eyes will be on Sweden as the country takes over the presidency of the EU. All signs points to the coming spring being very eventful as many crucial issues are to be addressed. Among other things, there will be a major review of the common European regulatory framework for medicines.Read the full article on the crucial EU issues at  biostock.se/en: https://www.biostock.se/en/2022/10/important-year-for-life-science-as-sweden-holds-the-eu-presidency 

Nordic Paper increases ambition in its climate targets

Nordic Paper has adopted new targets for reduction of its climate impact. The total emissions of fossil greenhouse gases from Nordic Paper activities, including indirect emissions from purchased goods and services, are to be reduced by 50% to 2030 compared with 2020. In addition, the direct emissions from the company’s own activity and from purchased energy are to be reduced by at least 50% for the same period of time. Nordic Paper manufactures specialised kraft papers and natural greaseproof papers for use primarily in the food sector. The papers are produced from locally sourced

There are no items matching the current filter
There are no more items matching the current filter
Back to top